Pliant Therapeutics

pliantrx.com

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies for fibrotic diseases. With a strong pipeline that includes the first clinical stage, oral, selective small molecule integrin inhibitor, Pliant aims to transform the treatment landscape for conditions like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The company is led by a team of experts in fibrosis and drug development, committed to understanding the molecular drivers of these diseases to create safer and more effective therapies. Pliant's innovative approach and dedication to patient outcomes position it as a leader in the fibrosis treatment market.

Is this your company?